Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Published:2018-11 Issue:11 Volume:19 Page:1480-1492
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hodi Frank Stephen,Chiarion-Sileni Vanna,Gonzalez Rene,Grob Jean-Jacques,Rutkowski Piotr,Cowey Charles Lance,Lao Christopher D,Schadendorf Dirk,Wagstaff John,Dummer Reinhard,Ferrucci Pier Francesco,Smylie Michael,Hill Andrew,Hogg David,Marquez-Rodas Ivan,Jiang Joel,Rizzo Jasmine,Larkin James,Wolchok Jedd D

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Systematic review of medical treatment in melanoma: current status and future prospects;Garbe;Oncologist,2011

2. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

3. Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAFV600-mutant melanoma;Chapman;J Clin Oncol,2017

4. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study;Chapman;Ann Oncol,2017

5. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

Cited by 1100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Immunotherapeutic strategies for the treatment of colorectal cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

4. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

5. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study);European Journal of Cancer;2024-11